Biomed Central Ltd

SHERPA: Unknown

People

  1. Wolchok
    Wolchok
  2. Vickers
    Vickers
  3. Merghoub
    Merghoub
  4. Postow
    Postow
  5. Offit
    Offit
  6. Zamarin
    Zamarin
  7. Chan
    Chan
  8. Hadjantonakis
    Hadjantonakis
  9. Voss
    Voss
  10. Budhu
    Budhu

Groups

  1. Solid Tumor Oncology Division (231)
  2. Population Sciences Research Program (114)
  3. Epidemiology and Biostatistics (106)
  4. Sloan Kettering Institute Postdocs (103)
  5. Sloan Kettering Institute Faculty (102)
  6. Melanoma and Immunotherapeutics Service (85)
  7. Survivorship Research (78)
  8. Surgery (76)
  9. Center for Hematologic Malignancies (52)
  10. Biostatistics Service (47)
Search Within
Refine Results
Formats
  1. Journal Article (520)
  2. Meeting Abstract (144)
  3. Conference Paper (1)
Groups
  1. Solid Tumor Oncology Division (231)
  2. Population Sciences Research Program (114)
  3. Epidemiology and Biostatistics (106)
  4. Sloan Kettering Institute Postdocs (103)
  5. Sloan Kettering Institute Faculty (102)
  6. Melanoma and Immunotherapeutics Service (85)

More Groups

People
  1. Jedd Wolchok (56)
  2. Andrew Vickers (39)
  3. Taha Merghoub (34)
  4. Michael Postow (26)
  5. Matthew Hellmann (17)
  6. Roberta Zappasodi (17)

More People

Years
  1. 2020 (35)
  2. 2019 (70)
  3. 2018 (59)
  4. 2017 (75)
  5. 2016 (75)
  6. 2015 (49)

More Years

Publications
  1. Journal for ImmunoTherapy of Cancer (185)
  2. Breast Cancer Research (55)
  3. BMC Cancer (48)
  4. Genome Biology (36)
  5. BMC Bioinformatics (25)
  6. Journal of Translational Medicine (24)

More Publications

Results (665)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial
    Journal Article

    Motzer, R. J.; Escudier, B.; McDermott, D. F.; Frontera, O. A.; Melichar, B.; Powles, T.; Donskov, F.; Plimack, E. R.; Barthélémy, P.; Hammers, H. J.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
    Journal Article

    Shah, N.; Aiello, J.; Avigan, D. E.; Berdeja, J. G.; Borrello, I. M.; Chari, A.; Cohen, A. D.; Ganapathi, K.; Gray, L.; Green, D.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy
    Journal Article

    Ged, Y.; Chaim, J. L.; DiNatale, R. G.; Knezevic, A.; Kotecha, R. R.; Carlo, M. I.; Lee, C. H.; Foster, A.; Feldman, D. R.; Teo, M. Y.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: A multicenter, retrospective study
    Journal Article

    Najjar, Y. G.; Navrazhina, K.; Ding, F.; Bhatia, R.; Tsai, K.; Abbate, K.; Durden, B.; Eroglu, Z.; Bhatia, S.; Park, S.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • GUIP1: A R package for dose escalation strategies in phase I cancer clinical trials
    Journal Article

    Dinart, D.; Fraisse, J.; Tosi, D.; Mauguen, A.; Touraine, C.; Gourgou, S.; Le Deley, M. C.; Bellera, C.; Mollevi, C.
    BMC Medical Informatics and Decision Making (2020)

    Fulltext@MSK | Save
  • Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinations
    Journal Article

    Ged, Y.; Gupta, R.; Duzgol, C.; Knezevic, A.; Shapnik, N.; Kotecha, R.; Voss, M. H.; Feldman, D. R.; Akin, O.; Patil, S.; more...
    BMC Urology (2020)

    Fulltext@MSK | Save
  • A phase 1 dose escalation study of PRS-343, a HER2/4-1bb bispecific molecule, in patients with HER2-positive malignancies
    Meeting Abstract

    Piha-Paul, S.; Bendell, J.; Tolcher, A.; Hurvitz, S.; Patnaik, A.; Shroff, R.; Pohlmann, P.; Zettl, M.; Hahn, N.; Krishnamurthy, A.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • Construction of the immune landscape of durable response to checkpoint blockade therapy by integrating publicly available datasets
    Meeting Abstract

    Rudqvist, N. P.; Zappasodi, R.; Wells, D.; Thorsson, V.; Cogdill, A.; Monette, A.; Najjar, Y.; Sweis, R.; Wennerberg, E.; Bommareddy, P.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: A phase II trial
    Journal Article

    Zamarin, D.; Walderich, S.; Holland, A.; Zhou, Q.; Iasonos, A. E.; Torrisi, J. M.; Merghoub, T.; Chesebrough, L. F.; Mcdonnell, A. S.; Gallagher, J. M.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: Primary analysis of fixed-dosing, long-term outcome of weight-based dosing
    Journal Article

    Rischin, D.; Migden, M. R.; Lim, A. M.; Schmults, C. D.; Khushalani, N. I.; Hughes, B. G. M.; Schadendorf, D.; Dunn, L. A.; Hernandez-Aya, L.; Chang, A. L. S.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save